R1VT34 Stock Overview
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Revvity, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.52 |
| 52 Week High | US$23.99 |
| 52 Week Low | US$14.51 |
| Beta | 1.09 |
| 1 Month Change | -0.80% |
| 3 Month Change | -0.80% |
| 1 Year Change | -18.77% |
| 3 Year Change | -29.83% |
| 5 Year Change | n/a |
| Change since IPO | 24.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| R1VT34 | BR Life Sciences | BR Market | |
|---|---|---|---|
| 7D | -0.8% | 0% | 0% |
| 1Y | -18.8% | 0% | 0% |
Return vs Industry: R1VT34 underperformed the BR Life Sciences industry which returned -2.2% over the past year.
Return vs Market: R1VT34 underperformed the BR Market which returned 13.2% over the past year.
Price Volatility
| R1VT34 volatility | |
|---|---|
| R1VT34 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in BR Market | 0% |
| 10% least volatile stocks in BR Market | 0% |
Stable Share Price: R1VT34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine R1VT34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1937 | 11,000 | Prahlad Singh | www.revvity.com |
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Revvity, Inc. Fundamentals Summary
| R1VT34 fundamental statistics | |
|---|---|
| Market cap | R$64.87b |
| Earnings (TTM) | R$933.38m |
| Revenue (TTM) | R$13.88b |
69.3x
P/E Ratio4.7x
P/S RatioIs R1VT34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R1VT34 income statement (TTM) | |
|---|---|
| Revenue | US$2.73b |
| Cost of Revenue | US$1.21b |
| Gross Profit | US$1.51b |
| Other Expenses | US$1.33b |
| Earnings | US$183.35m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.48 |
| Gross Margin | 55.52% |
| Net Profit Margin | 6.73% |
| Debt/Equity Ratio | 49.4% |
How did R1VT34 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield19%
Payout RatioDoes R1VT34 pay a reliable dividends?
See R1VT34 dividend history and benchmarks| Revvity dividend dates | |
|---|---|
| Ex Dividend Date | Jul 18 2024 |
| Dividend Pay Date | Aug 15 2024 |
| Days until Ex dividend | 70 days |
| Days until Dividend pay date | 98 days |
Does R1VT34 pay a reliable dividends?
See R1VT34 dividend history and benchmarks